IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Your view on IDXX
Overview
What the company does, where it operates, and who runs it.
About IDEXX Laboratories, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Jonathan J. Mazelsky
- Headquarters
- One IDEXX Drive, Westbrook, ME, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Jonathan J. Mazelsky
- Headquarters
- One IDEXX Drive, Westbrook, ME, US
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments.
It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits.
In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups.
The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for IDEXX Laboratories, Inc. from FRC's valuation model, read against the market price. IDXX last traded at $700.65, 47.4× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for IDEXX Laboratories, Inc.. Starting points for IDEXX Laboratories, Inc.: P/E 47.4, EPS $15.00, beta 1.54 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for IDEXX Laboratories, Inc.. Trailing twelve-month EPS for IDEXX Laboratories, Inc. stands at $15.00. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$741.67
average of 6 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy5
- Hold3
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $3.34 | $3.91 | $14.91 | $16.84 |
| Low estimate | $3.30 | $3.83 | $14.68 | $16.62 |
| High estimate | $3.38 | $4.02 | $14.97 | $17.03 |
| No. of analysts | 8 | 6 | 9 | 10 |
| Year-ago EPS | $3.08 | $3.47 | $13.08 | — |
| Growth | +8.4% | +12.7% | +14.0% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.18B | $1.22B | $4.75B | $5.16B |
| Low estimate | $1.17B | $1.21B | $4.72B | $5.11B |
| High estimate | $1.19B | $1.23B | $4.77B | $5.21B |
| No. of analysts | 8 | 5 | 11 | 11 |
| Year-ago revenue | $1.09B | $1.14B | $4.30B | — |
| Growth | +8.5% | +6.8% | +10.3% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ELANElanco Animal Health IncorporatedDrug Manufacturers - Specialty & Generic$13.2B
- MRKMerck & Co., Inc.Drug Manufacturers - General$356.1B
- NEOGNeogen CorporationMedical - Devices$2.4B
- ZTSZoetis Inc.Drug Manufacturers - Specialty & Generic$34.3B
More Medical - Diagnostics & Research companies
- MRPSMicrophonics, Inc.OTC
- MTDMettler-Toledo International Inc.NYSE$34.4B
- MVF.AXMonash IVF Group LimitedASX
- MYGNMyriad Genetics, Inc.NASDAQ$534M
- NDRAENDRA Life Sciences Inc.NASDAQ$7M
- NEONeoGenomics, Inc.NASDAQ$2.0B
- NSTMNovelStem International Corp.OTC$653,997
- NTRANatera, Inc.NASDAQ$41.8B
- OCLGOncologix Tech, Inc.OTC$73,662
- OPKOPKO Health, Inc.NASDAQ$1.2B
- PEB.AXPacific Edge LimitedASX
- PFGTFPacific Edge LimitedOTC$238M
ETFs holding IDEXX Laboratories, Inc.
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.07%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.06%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets0.26%
- VOVanguard Mid-Cap ETF$103.4B in assets0.42%
- PHOInvesco Water Resources ETF$2.1B in assets8.16%
- IHIiShares US Medical Devices ETF$4.0B in assets5.47%
- FIWFirst Trust Water ETF$1.9B in assets4.70%
- QQEWFirst Trust Nasdaq-100 Select Equal Weight ETF$1.6B in assets2.80%
Largest holders first, then the funds most concentrated in IDXX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold IDEXX Laboratories, Inc., and how their positions are changing. At a $55.20B market value, institutional positions materially move IDEXX Laboratories, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by IDEXX Laboratories, Inc. executives and directors. Shares of IDEXX Laboratories, Inc. have traded between $356.14 and $735.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming IDEXX Laboratories, Inc.. IDEXX Laboratories, Inc. is a $55.20B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming IDEXX Laboratories, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for IDEXX Laboratories, Inc.. Coverage tracks IDEXX Laboratories, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of IDEXX Laboratories, Inc.